TREA

79160465 - PETIZATION

Follow

Information

  • Trademark
  • 79160465
  • Serial Number
    79160465
  • Registration Number
    4879066
  • Filing Date
    August 27, 2014
    10 years ago
  • Registration Date
    January 05, 2016
    9 years ago
  • Transaction Date
    December 31, 2023
    a year ago
  • Status Date
    July 22, 2022
    2 years ago
  • Published for Opposition Date
    October 20, 2015
    9 years ago
  • Location Date
    January 05, 2016
    9 years ago
  • Status Code
    709
  • Current Location
    PUBLICATION AND ISSUE SECTION
    Employee Name
    GLASSER, CARYN
  • Attorney Docket Number
    New.New
    Law Office Assigned Location Code
    L80
  • Owners
Information
Mark Drawing Code
4000
Mark Identification
PETIZATION
Case File Statements
  • GS0051: Biological preparations for pharmaceutical purposes for the treatment of pain, itch, diabetes, cancer, and inflammation; pharmaceutical preparations for the treatment of pain, itch, diabetes, cancer, and inflammation; pharmaceutical preparations for animals for the treatment of pain, itch, diabetes, cancer, and inflammation; pharmaceutical preparations for veterinary use for the treatment of pain, itch, diabetes, cancer, and inflammation; radioactive preparations for veterinary use for the treatment of pain, itch, diabetes, cancer, and inflammation; reagents for in-vitro laboratory use for medical diagnostic veterinary purposes; reagents for laboratory purposes for medical diagnostic veterinary purposes; reagents for use in analytical tests for medical diagnostic veterinary purposes; reagents for use in diagnostic tests for medical diagnostic veterinary purposes; reagents for use in the development of monoclonal antibodies for medical diagnostic veterinary purposes; reagents in kit form for conducting enzyme-linked immunosorbent assays (ELISA) for medical diagnostic veterinary purposes; veterinary preparations for the treatment of pain, itch, diabetes, cancer, and inflammation; veterinary preparations for administration by injection for the treatment of pain, itch, diabetes, cancer, and inflammation; veterinary preparations for immunisation against disease; veterinary preparations for use in improving the skin; veterinary preparations for use in treating the coat; veterinary preparations in dosage forms for veterinary use for the treatment of pain, itch, diabetes, cancer, and inflammation; veterinary products, namely, 100% species-specific monoclonal antibodies, canine or feline fusion proteins, and canine or feline insulin analogues; veterinary products for equines, namely, fully equinized monoclonal antibodies, equine fusion proteins; veterinary vaccines; biological preparations for veterinary purposes for the treatment of pain, itch, diabetes, cancer, and inflammation; antibodies for pain, itch, diabetes, cancer, and inflammation; immunological antibodies for medical use for the treatment of cancer; monoclonal antibodies for medical diagnostic use; monoclonal antibodies for medical use for pain, itch, diabetes, cancer, and inflammation; monoclonal antibodies for therapeutic purposes for the treatment of pain, itch, diabetes, cancer, and inflammation; products containing antibodies for use in medicine for pain, itch, diabetes, cancer, and inflammation; reagents for use in the development of monoclonal antibodies for medical diagnostic purposes; monoclonal antibodies for medical use for diagnostic purposes for pain, itch, diabetes, cancer and inflammation; biological preparations for medical purposes for the treatment of pain, itch, diabetes, cancer, and inflammation; biological products for medical use, namely, 100% species-specific monoclonal antibodies, canine or feline fusion proteins, and canine or feline insulin analogues for the treatment of pain, itch, diabetes, cancer, and inflammation; biological reagents for medical diagnostic purposes for use in molecular biology; biological substances for medical use, namely, 100% species-specific monoclonal antibodies, canine or feline fusion proteins, and canine or feline insulin analogues for the treatment of pain, itch, diabetes, cancer, and inflammation; reagents for use in biological processing for medical diagnostic purposes; reagents for use in biological processing for medical diagnostic purposes for veterinary purposes; therapeutic biological products, namely, 100% species-specific monoclonal antibodies, canine or feline fusion proteins, and canine or feline insulin analogues for the treatment of pain, itch, diabetes, cancer, and inflammation; monoclonal antibody reagents for medical diagnostic use; medical therapeutic agents for the treatment of pain, itch, diabetes, cancer, and inflammation; medical therapeutic drugs for the treatment of pain, itch, diabetes, cancer, and inflammation; animal care products for veterinary use, namely, 100% species-specific monoclonal antibodies, canine or feline fusion proteins, and canine or feline insulin analogues or recombinant proteins for the treatment of pain, itch, diabetes, cancer, and inflammation; biotechnological preparations for veterinary use, namely, 100% species-specific monoclonal antibodies, canine or feline fusion proteins, and canine or feline insulin analogues for the treatment of pain, itch, diabetes, cancer, and inflammation
  • GS0421: Pharmaceutical research services; research relating to pharmaceuticals; services for assessing the efficiency of pharmaceuticals, namely, molecular binding, stability, immunogenicity and potency assays; services for assessing the safety of pharmaceuticals, namely, animal model and in-species clinical studies; services for assessing the efficiency of veterinary drugs, namely, molecular binding, stability, immunogenicity and potency assays and proof-of-concept and field studies; veterinary laboratory services; advisory services relating to scientific research, namely, advice in the field of therapeutic biologic drug candidate selection and development; laboratory services, namely, laboratory services for scientific research services and analysis of therapeutic biologic drugs; scientific laboratory services; scientific research; scientific research in the field of pharmacy; biological research; services for assessing the safety of veterinary drugs, namely, animal model and in-species clinical studies; provision of information relating to scientific research, namely, information on the identification and development of therapeutic biologic drug candidates
Case File Event Statements
  • 12/31/2023 - a year ago
    37 - NEW REPRESENTATIVE AT IB RECEIVED Type: NREP
  • 10/20/2023 - a year ago
    36 - NEW REPRESENTATIVE AT IB RECEIVED Type: NREP
  • 5/22/2023 - a year ago
    35 - TOTAL INVALIDATION PROCESSED BY THE IB Type: INNT
  • 5/1/2023 - a year ago
    34 - TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB Type: INTS
  • 4/30/2023 - a year ago
    33 - INVALIDATION PROCESSED Type: INPC
  • 3/22/2023 - a year ago
    32 - TOTAL INVALIDATION OF REG EXT PROTECTION CREATED Type: INTR
  • 7/22/2022 - 2 years ago
    31 - CANCELLED SECTION 71 Type: C71T
  • 9/24/2021 - 3 years ago
    30 - CHANGE OF OWNER RECEIVED FROM IB Type: CHLD
  • 1/5/2021 - 4 years ago
    29 - COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED Type: REM3
  • 1/2/2021 - 4 years ago
    28 - NEW REPRESENTATIVE AT IB RECEIVED Type: NREP
  • 12/30/2016 - 8 years ago
    27 - CHANGE OF OWNER RECEIVED FROM IB Type: CHLD
  • 7/8/2016 - 8 years ago
    26 - FINAL DECISION TRANSACTION PROCESSED BY IB Type: FINO
  • 4/7/2016 - 8 years ago
    25 - FINAL DISPOSITION NOTICE SENT TO IB Type: FICS
  • 4/7/2016 - 8 years ago
    24 - FINAL DISPOSITION PROCESSED Type: FIMP
  • 4/5/2016 - 8 years ago
    23 - FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Type: FICR
  • 1/5/2016 - 9 years ago
    22 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 10/20/2015 - 9 years ago
    21 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 10/20/2015 - 9 years ago
    20 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 10/17/2015 - 9 years ago
    19 - NOTIFICATION PROCESSED BY IB Type: GPNX
  • 9/30/2015 - 9 years ago
    18 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS
  • 9/30/2015 - 9 years ago
    17 - NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB Type: OP2R
  • 9/30/2015 - 9 years ago
    16 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 9/16/2015 - 9 years ago
    15 - LAW OFFICE PUBLICATION REVIEW COMPLETED Type: PREV
  • 9/14/2015 - 9 years ago
    14 - ASSIGNED TO LIE Type: ALIE
  • 8/20/2015 - 9 years ago
    13 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 8/18/2015 - 9 years ago
    12 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 8/18/2015 - 9 years ago
    11 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 8/18/2015 - 9 years ago
    10 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 3/13/2015 - 9 years ago
    9 - REFUSAL PROCESSED BY IB Type: RFNP
  • 2/27/2015 - 9 years ago
    8 - APPLICATION FILING RECEIPT MAILED Type: MAFR
  • 2/26/2015 - 9 years ago
    7 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS
  • 2/26/2015 - 9 years ago
    6 - REFUSAL PROCESSED BY MPU Type: RFRR
  • 2/26/2015 - 9 years ago
    5 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR
  • 2/25/2015 - 9 years ago
    4 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 2/23/2015 - 9 years ago
    3 - ASSIGNED TO EXAMINER Type: DOCK
  • 2/23/2015 - 9 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 2/20/2015 - 9 years ago
    1 - SN ASSIGNED FOR SECT 66A APPL FROM IB Type: REPR